TherapeuticsMD (TXMD) Cost of Revenue (2011 - 2023)

TherapeuticsMD's Cost of Revenue history runs 13 years deep, the most recent figure standing at -$33000.0 for Q4 2023.

• Quarterly Cost of Revenue changed N/A year-over-year to -$33000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $73000.0 (down 94.77% YoY) and the FY2022 annual result came in at $1.4 million, changed 0.36% from the prior year.
• Cost of Revenue was -$33000.0 for Q4 2023 at TherapeuticsMD, down from $106000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.6 million in Q4 2020 and bottomed at -$12.7 million in Q4 2021.
• A 5-year average of $1.5 million and a median of $1.4 million in 2019 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2020 — Cost of Revenue soared 255.91% — and 2021, when it plunged 327.54%.
• TherapeuticsMD's Cost of Revenue stood at $2.9 million in 2019, then surged by 93.85% to $5.6 million in 2020, then plunged by 327.54% to -$12.7 million in 2021, then jumped by 102.79% to $354000.0 in 2022, then sank by 109.32% to -$33000.0 in 2023.
• Business Quant data shows TXMD's Cost of Revenue at -$33000.0 in Q4 2023, $106000.0 in Q3 2023, and $354000.0 in Q3 2022.